US · guidance
CMS SOM App. J, Tag W311
§483.450(e)(2) be approved by the interdisciplinary team and
Guidance §483.450(e)(2)
The physician and other team members discuss the risks and benefits of the medication to
address the target behavior/symptoms, and approve the use of the drug as being consistent
with the active treatment program. Decisions about the necessity of the use of drugs to manage
inappropriate behavior should be made by the IDT. It is the responsibility of the IDT members to
provide the physician with sufficient information regarding the need for a client to receive a
drug for inappropriate behavior. The physician will make the ultimate decision to order the use
of the drug. The IDT should document any disagreement with the physician’s order.
In those instances where a client returns from a physician’s visit with an order for an unsolicited
drug to manage client’s inappropriate behaviors, there must be evidence (e.g. IDT meeting
notes or clients record) that the team concurred with the necessity for the order without trying
less restrictive measures first and discussed any concerns with the physician.
History
Rev. 135, Issued: 02-27-15, Effective: 04-27-15, Implementation: 04-27-15
Provenance
- Source
- cms.gov
- Retrieved
- 2026-07-22
- Edition
- som-2026-07-22
- Content hash
65817a55eb3bf80e4a45bc01c0ca0a37c7fc7a98b72f9cb8cb563ee9ed6b43af
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.